Identification and Validation of Lymphovascular Invasion as a Prognostic and Staging Factor in Node-Negative Esophageal Squamous Cell Carcinoma Qingyuan.

Slides:

Advertisements

Similar presentations

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Mian Xi, MD, Zhongxing.

Advertisements

Outcomes of Primary Squamous Cell Carcinoma of Major Salivary Glands Treated by Surgery With or Without Postoperative Radiotherapy Lina Wang, MD, Hao.

Assessment of Lymph Node Ratio to Replace the pN Categories System of Classification of the TNM System in Esophageal Squamous Cell Carcinoma Yingjie.

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung Sai-Hong.

Radiation Therapy for Invasive Breast Cancer Increases the Risk of Second Primary Lung Cancer: A Nationwide Population-Based Cohort Analysis Yi-Jhih.

Primary Mucoepidermoid Carcinoma of the Esophagus

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus Yang Zhao, MD, ZhiJun Dai,

Do tumor location and grade affect survival in pT2N0M0 esophageal squamous cell carcinoma? Dongrong Situ, MD, Junye Wang, MD, PhD, Peng Lin, MD, PhD,

The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals Regarding the Clinical Staging of Small Cell Lung Cancer.

Ratio of Metastatic Lymph Nodes to Total Number of Nodes Resected is Prognostic for Survival in Esophageal Carcinoma Clive J. Kelty, MB, ChB, PhD, FRCSEd,

Local recurrence after surgery for non–small cell lung cancer: A recursive partitioning analysis of multi-institutional data Chris R. Kelsey, MD, Kristin.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Impact of Solid Minor Histologic Subtype in Postsurgical Prognosis of Stage I Lung Adenocarcinoma Tianxiang Chen, MD, PhD, Jizhuang Luo, MD, Haiyong.

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Shidan Wang, BS, Lin Yang, MD, Bo Ci, BS, Matthew Maclean, BS, David E

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Prognostic significance of histologic differentiation, carcinoembryonic antigen value, and lymphovascular invasion in stage I non–small cell lung cancer

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Postchemoradiotherapy Pathologic Stage Classified by the American Joint Committee on the Cancer Staging System Predicts Prognosis of Patients with Locally.

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

The Impact of Postoperative Conformal Radiotherapy after Radical Surgery on Survival and Recurrence in Pathologic T3N0M0 Esophageal Carcinoma: A Propensity.

Prognostic Variables in Thoracic Esophageal Squamous Cell Carcinoma

Pattern of lymphatic spread in thoracic esophageal squamous cell carcinoma: A single- institution experience Bin Li, MD, Haiquan Chen, MD, Jiaqing Xiang,

Pretreatment Anemia Portends Poor Survival and Nonlocal Disease Progression in Patients with Stage I Non–Small Cell Lung Cancer Treated with Stereotactic.

Prognostic Factors in Completely Resected Node-Negative Lung Adenocarcinoma of 3 cm or Smaller Jung-Jyh Hung, MD, PhD, Yi-Chen Yeh, MD, Yu-Chung Wu,

Appraisal of a Revised Lymph Node Classification System for Esophageal Squamous Cell Cancer Dipok Kumar Dhar, PhD, Shinji Hattori, MD, Yasuhito Tonomoto,

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Primary Mucoepidermoid Carcinoma of the Esophagus

Predictors of Death, Local Recurrence, and Distant Metastasis in Completely Resected Pathological Stage-I Non–Small-Cell Lung Cancer Jung-Jyh Hung, MD,

Comprehensive Computational Pathological Image Analysis Predicts Lung Cancer Prognosis Xin Luo, MD, Xiao Zang, BS, Lin Yang, MD, Junzhou Huang, PhD,

Prevalence, Prognostic Implications, and Survival Modulators of Incompletely Resected Non–Small Cell Lung Cancer in the U.S. National Cancer Data Base

Lung Cancer and Prognosis in Taiwan: A Population-Based Cancer Registry Bing-Yen Wang, MD, Jing-Yang Huang, Ching-Yuan Cheng, MD, Ching-Hsiung Lin, MD,

Prognostic Impact of Preoperative Tumor Marker Levels and Lymphovascular Invasion in Pathological Stage I Adenocarcinoma and Squamous Cell Carcinoma of.

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition Sai-Hong.

Prophylactic Cranial Irradiation for Patients with Surgically Resected Small Cell Lung Cancer Jianlin Xu, MD, Haitang Yang, MD, Xiaolong Fu, MD, Bo Jin,

Lung Adenocarcinomas Manifesting as Radiological Part-Solid Nodules Define a Special Clinical Subtype Ting Ye, MD, PhD, Lin Deng, MD, Shengping Wang,

Lung adenocarcinoma: Are skip N2 metastases different from non-skip?

Comparison of the 6th and 7th Editions of the American Joint Committee on Cancer Tumor-Node-Metastasis Staging System in Patients With Resected Esophageal.

Yang Zhang, MD, Haiquan Chen, MD, PhD

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small.

Explore the Radiotherapeutic Clinical Target Volume Delineation for Thoracic Esophageal Squamous Cell Carcinoma from the Pattern of Lymphatic Metastases

Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter.

Thoracoscopic Lobectomy Produces Long-Term Survival Similar to That with Open Lobectomy in Cases of Non–Small Cell Lung Carcinoma: A Propensity-Matched.

Nodal Skip Metastasis in Esophageal Squamous Cell Carcinoma Patients Undergoing Three-Field Lymphadenectomy Feng Wang, MD, Yuzhen Zheng, MD, Zhen Wang,

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Prognostic Impact of Node Involvement Pattern in Pulmonary pN1 Squamous Cell Carcinoma Patients Masayuki Nakao, MD, Junji Yoshida, MD, PhD, Genichiro.

Assessment of Lymph Node Ratio to Replace the pN Categories System of Classification of the TNM System in Esophageal Squamous Cell Carcinoma Yingjie.

Prognostic Impact of Preoperative Tumor Marker Levels and Lymphovascular Invasion in Pathological Stage I Adenocarcinoma and Squamous Cell Carcinoma of.

High Expression of p300 Has an Unfavorable Impact on Survival in Resectable Esophageal Squamous Cell Carcinoma Yong Li, MD, Hao-Xian Yang, MD, Rong-Zhen.

Clinical Utility of the Pretreatment Glasgow Prognostic Score in Patients with Advanced Inoperable Non-small Cell Lung Cancer Elaine Y.L. Leung, MB ChB,

Tumor-Stroma Ratio Is an Independent Predictor for Survival in Esophageal Squamous Cell Carcinoma kai Wang, MD, Wei Ma, MD, Jianbo Wang, MD, Liang Yu,

Multiple Primary Cancers or Multiple Metastases, That Is the Question

Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang,

Does Lymph Node Metastasis Have a Negative Prognostic Impact in Patients with NSCLC and M1a Disease? Chenyang Dai, MD, Yijiu Ren, MD, Dong Xie, MD, PhD,

Surgical Treatment for Limited-Stage Primary Small Cell Cancer of the Esophagus Dongrong Situ, MD, Yongbin Lin, MD, PhD, Hao Long, MD, PhD, Lanjun Zhang,

Clinical Relevance of Our Multimodality Prognostic Score

It’s All in the “Swerve of the Curve”

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Mian Xi, MD, Zhongxing.

Influence of Ground Glass Opacity and the Corresponding Pathological Findings on Survival in Patients with Clinical Stage I Non–Small Cell Lung Cancer

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Detailed Analysis of Prognostic Factors in Primary Esophageal Small Cell Carcinoma Wei-Wei Chen, MD, Feng Wang, MD, PhD, ShaoBin Chen, MD, Luhua Wang,

Population-Based Patterns of Surgical Care for Stage IIIA NSCLC in the Netherlands between 2010 and 2013 Chris Dickhoff, MD, Max Dahele, MBChB., PhD,

Postchemoradiotherapy Pathologic Stage Classified by the American Joint Committee on the Cancer Staging System Predicts Prognosis of Patients with Locally.

Presentation transcript:

Identification and Validation of Lymphovascular Invasion as a Prognostic and Staging Factor in Node-Negative Esophageal Squamous Cell Carcinoma Qingyuan Huang, MD, Kongjia Luo, MD, PhD, Chun Chen, MD, PhD, Geng Wang, MD, Jietian Jin, MD, Min Kong, MD, Bifeng Li, MD, Qianwen Liu, MD, Jinhui Li, MB, Tiehua Rong, MD, PhD, Haiquan Chen, MD, PhD, Lanjun Zhang, MD, PhD, Yuping Chen, MD, PhD, Chengchu Zhu, MD, PhD, Bin Zheng, MD, Jing Wen, MD, PhD, Yuzhen Zheng, MD, Zihui Tan, MD, Xiuying Xie, BE, Hong Yang, MD, PhD, Jianhua Fu, MD, PhD Journal of Thoracic Oncology Volume 11, Issue 4, Pages 583-592 (April 2016) DOI: 10.1016/j.jtho.2015.12.109 Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Kaplan-Meier survival analysis. (A) Disease-specific survival and (B) disease-free survival curves for patients in the primary cohort according to lymphovascular invasion status. (C) Node-negative and (D) node-positive subsets of the primary cohort according to lymphovascular invasion status. LVI, lymphovascular invasion. Journal of Thoracic Oncology 2016 11, 583-592DOI: (10.1016/j.jtho.2015.12.109) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Time-dependent receiver operating characteristic analysis. The area under the curve for the risk score involving the combination of lymphovascular invasion status and the T classification remained higher than those for the tumor, node, and metastasis system and other factors alone among node-negative patients in the primary cohort (A) and the validation cohort (B). LVI, lymphovascular invasion; TNM, tumor, node, and metastasis; T, tumor. Journal of Thoracic Oncology 2016 11, 583-592DOI: (10.1016/j.jtho.2015.12.109) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 3 (A) Disease-specific survival curves for T2–3N0M0 disease according to the stage in the seventh edition of the staging system for esophageal carcinoma. (B) Disease-specific survival curves for T2N0M0 without lymphovascular invasion (LVI), T2N0M0 with LVI, and T2N1M0 disease. (C) Disease-specific survival curves for T3N0M0 without LVI, T3N0M0 with LVI, and T3N1M0 disease. (D) Disease-specific survival curves for T1N0M0 without LVI, T1N0M0 with LVI, and T1N1M0 disease. LVI, lymphovascular invasion. Journal of Thoracic Oncology 2016 11, 583-592DOI: (10.1016/j.jtho.2015.12.109) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions